Dexlansoprazole

What it is

Dexlansoprazole is the R-enantiomer (one of the two mirror-image forms) of the older proton pump inhibitor lansoprazole, supplied as a capsule of two sorts of delayed-release granules. It belongs to the substituted benzimidazoles, a class of antisecretory drugs that block the stomach's acid pump. It is a prescription medicine, not a nutrient or food component; the capsules are made in 30 mg and 60 mg strengths. It is approved in the United States for people aged 12 and over.

What the research says

The evidence is strongest for healing and keeping healed the acid-damaged oesophagus (erosive esophagitis) and for reducing heartburn in reflux disease; a 2024 systematic review of ten randomised trials rated the certainty of that evidence as moderate and warned that the number of trials was small. Head-to-head against esomeprazole it has not shown a clear advantage for healing. The important uncertainties are about long-term use: large observational datasets link years of proton pump inhibitor use to fractures, kidney disease, low magnesium and vitamin B12 and Clostridioides difficile infection, while the one large randomised trial of a proton pump inhibitor against placebo over three years found an increase only in enteric infections. Stopping after eight weeks can itself produce heartburn in people who never had it, which is a trap for staying on the drug indefinitely.

Evidence grade: Well established.

How it works

Drug class: Proton pump inhibitor (substituted benzimidazole); the R-enantiomer of lansoprazole in a dual delayed-release formulation

Dexlansoprazole shuts down the enzyme that pumps acid into the stomach. It is taken up by the acid-producing (parietal) cells of the stomach lining and binds the hydrogen/potassium ATPase - the proton pump - which is the last step in making stomach acid, so the stomach contents become much less acidic. The dual delayed-release capsule contains two kinds of granules that dissolve at two different points in the gut, giving two blood-level peaks instead of one. (Source 1)

What it is used for

• Randomised trials support 60 mg once daily for up to eight weeks for healing the eroded oesophagus. A 2024 systematic review of ten randomised trials found dexlansoprazole better than placebo for heartburn and reflux symptoms with moderate certainty, but a 2019 head-to-head trial found no difference from esomeprazole in sustained healing at 24 weeks. Evidence: established. (Source 2)
• 30 mg once daily is approved to keep the oesophagus healed, with controlled studies running to six months in adults and 16 weeks in 12 to 17 year olds. In adolescents healing was maintained in 82% on dexlansoprazole versus 58% on placebo. Evidence: established. (Source 3)
• Approved for four weeks at 30 mg. The meta-analysis for heartburn-free days and nights rested on only three trials with very high statistical heterogeneity, and one included trial found no statistically significant difference from placebo. Evidence: limited. (Source 2)
• Proton pump inhibitors are widely used long term for functional dyspepsia and non-erosive reflux. A 2025 narrative evidence-based review names exactly these groups as the ones in whom guidelines advise dose reduction, intermittent use or a switch to an H2-receptor antagonist rather than continued daily therapy. Evidence: limited. (Source 4)
• Not an approved indication for dexlansoprazole, but proton pump inhibitors are used for it; the 2025 narrative review lists eosinophilic oesophagitis among the conditions in which proton pump inhibitors are not routinely deprescribed, implying a maintained treatment role rather than a trial-proven one. Evidence: limited. (Source 5)

Interactions

• St John's wort (label): St John's wort induces the liver enzymes that clear dexlansoprazole, so blood levels of the drug fall and it may stop working. The label tells prescribers to avoid the combination. (Source 6)
• Iron salts and other supplements or drugs that need stomach acid to dissolve (label): By raising stomach pH, dexlansoprazole can reduce how much of an acid-dependent product is absorbed. Iron salts are named on the label. (Source 7)
• Magnesium and vitamin B12 (case reports): Long-term acid suppression is associated with low blood magnesium and with vitamin B12 deficiency, because acid is needed to free B12 from food protein and to absorb minerals. This is observational, not a controlled interaction study. (Source 8)
• Food and meals (pharmacokinetic study): Eating changes how much dexlansoprazole gets into the blood, but not enough to matter: the label concludes it can be taken with or without food. (Source 9)
• Alcohol (label): No alcohol interaction is listed among the clinically important interactions in the February 2025 label, and we found no controlled study of alcohol with dexlansoprazole. Alcohol is itself a cause of reflux symptoms, which is a separate matter from a drug interaction. (Source 10)
• Warfarin (label): Proton pump inhibitors taken with warfarin have raised the INR and prothrombin time, which can mean abnormal bleeding. (Source 11)
• High-dose methotrexate (label): Proton pump inhibitors may raise and prolong methotrexate levels, risking methotrexate toxicity; the label notes no formal interaction study has been done. (Source 11)

Stopping it

• A randomised placebo-controlled trial in 120 healthy volunteers showed that eight weeks of a proton pump inhibitor produces heartburn, acid regurgitation or dyspepsia after it is stopped, in people who had no such symptoms to begin with. This rebound can be mistaken for the original disease returning. (Source 12)
• A 2025 evidence-based review states that dose reduction, on-demand use or stopping should be routinely considered once the initial course is finished, and lists the conditions in which stopping is not appropriate. (Source 13)
• Guideline positions summarised in that review hold that both a gradual taper and simply stopping are acceptable, and that the decision should turn on the indication rather than on fear of side effects. (Source 5)
• The same review's own knowledge-gaps section concedes that which stopping strategy is best has not been settled by adequate evidence. Two things to keep in mind about this source: it describes itself as a narrative review rather than a systematic one, and the numbered citations in this part of the article are scrambled - the numbers it gives for fracture, kidney and infection risk point to papers on other subjects in its own reference list - so what is reliable here is the statement that the gap exists, not the sources it names for it. (Source 14)

What goes wrong

In the manufacturer's pooled controlled trials, diarrhoea, abdominal pain, nausea, upper respiratory infection, vomiting and flatulence each occurred more often on dexlansoprazole than placebo, all at single-digit percentages. (Source 15)

• Official position, Moderate certainty.
• Size: 896 on placebo, 455 on 30 mg, 2,218 on 60 mg, 1,363 on lansoprazole 30 mg.
• Who: adults in six randomised controlled trials of erosive esophagitis, maintenance and symptomatic GERD.
• How long: up to one year in the wider safety database.
• Result: diarrhoea 4.8% total drug vs 2.9% placebo; abdominal pain 4.0% vs 3.5%; nausea 2.9% vs 2.6%; upper respiratory tract infection 1.9% vs 0.8%; vomiting 1.6% vs 0.8%; flatulence 1.6% vs 0.6%; discontinuation for diarrhoea 0.7%.
• Funding: industry - manufacturer's own trials, reported in the FDA label.

Limit of this finding: The label's own table does not add up: the combined column is headed "DEXILANT Total (N=2621)" while the two dose columns it combines are 455 and 2,218 patients, which come to 2,673. The figures here are reproduced exactly as the FDA label prints them, so the percentages should be read as the label's own and no rate should be recalculated from these denominators.

The most common adverse reactions (≥2%) that occurred at a higher incidence for DEXILANT than placebo in the controlled studies are presented in Table 2 . Table 2. Common Adverse Reactions in Controlled Studies in Adults Adverse Reaction Placebo (N=896) % DEXILANT 30 mg (N=455) % DEXILANT 60 mg (N=2218) % DEXILANT Total (N=2621) % Lansoprazole 30 mg (N=1363) % Diarrhea 2.9 5.1 4.7 4.8 3.2 Abdominal Pain 3.5 3.5 4.0 4.0 2.6 Nausea 2.6 3.3 2.8 2.9 1.8 Upper Respiratory Tract Infection 0.8 2.9 1.7 1.9 0.8 Vomiting 0.8 2.2 1.4 1.6 1.1 Flatulence 0.6 2.6 1.4 1.6 1.2 Adverse Reactions Resulting in Discontinuation In controlled clinical studies, the most common adverse reaction leading to discontinuation from DEXILANT was diarrhea (0.7%).

In adolescents, treatment-emergent adverse events were common on dexlansoprazole but occurred at a similar rate on placebo. (Source 3)

• Randomized trial, Low certainty.
• Size: 62 adolescents in the open-label healing phase; 25 on dexlansoprazole and 26 on placebo in maintenance.
• Who: patients aged 12 to 17 with erosive esophagitis.
• How long: 8-week open healing phase, 16-week double-blind maintenance.
• Result: 61.3% reported a treatment-emergent adverse event during healing (headache 12.9%, oropharyngeal pain 8.1%, diarrhoea 6.5%); in maintenance 72.0% on dexlansoprazole versus 61.5% on placebo; no deaths.
• Funding: industry - manufacturer-sponsored safety study.

Results 88% of patients achieved EE healing, and 61.3% reported a TEAE [headache (12.9%), oropharyngeal pain (8.1%), diarrhea (6.5%), and nasopharyngitis (6.5%)]. During maintenance phase, healing was maintained in 82% and 58% of dexlansoprazole and placebo groups, respectively. 72.0% of dexlansoprazole-treated patients reported TEAEs, which included headache (24.0%), abdominal pain (12.0%), nasopharyngitis (12.0%), pharyngitis (12.0%), sinusitis (12.0%), bronchitis (8.0%), upper respiratory tract infection (8.0%), and insomnia (8.0%); 61.5% experienced a TEAE with placebo.

In the only large placebo-controlled randomised trial of a proton pump inhibitor over three years, the drug increased enteric infections by about 0.4 percentage points in absolute terms. (Source 16)

• Randomized trial, High certainty.
• Size: 17,598 participants (8,791 pantoprazole, 8,807 placebo), 53,152 patient-years.
• Who: adults with stable cardiovascular disease and peripheral artery disease.
• How long: median 3.01 years.
• Result: enteric infections 1.4% on pantoprazole versus 1.0% on placebo, odds ratio 1.33 (95% CI 1.01-1.75), an absolute difference of about 0.4 percentage points over three years.
• Funding: not stated in the abstract we read; the trial is the COMPASS programme (NCT01776424)

There was no statistically significant difference between the pantoprazole and placebo groups in safety events except for enteric infections (1.4% vs 1.0% in the placebo group; odds ratio, 1.33; 95% confidence interval, 1.01-1.75).

A 2025 narrative review reports that observational studies link proton pump inhibitors to Clostridioides difficile infection, citing pooled odds ratios of roughly 1.3 to 2.3 from an umbrella review of other researchers' meta-analyses. (Source 17)

• Expert review, not systematic, Low certainty.
• Size: the review's summary of one systematic review and meta-analysis plus a 2025 umbrella review of 11 meta-analyses; counts not given in the passage.
• Who: proton pump inhibitor users, including hospitalised patients.
• How long: short-term risk per the review's own classification.
• Result: as the review reports them: about a 1.7-fold increased risk of C. difficile-associated diarrhoea in the studies behind the FDA warning, and pooled odds ratios of approximately 1.3 to 2.3 in the umbrella review; the review states that the dose-response relationship and any threshold dose remain unclear.
• Funding: not stated.

Limit of this finding: This passage is the review summarising other people's work, and the review's own numbered citations for it point at the wrong papers: the C. difficile meta-analysis it credits appears in its own reference list as a study of anaemia, and the umbrella review is cited twice, the second time under a number belonging to a hip-fracture study. The odds ratios are given here as the review states them, but none of the papers this review names has been shown to establish them, and the underlying evidence is observational, so it shows an association rather than cause.

PPIs are strongly linked to an increased risk of enteric infections. The FDA issued a warning based on studies showing a ~1.7-fold increased risk of C. difficile -associated diarrhoea. A recent systematic review and meta-analysis indicated a positive association of CDI with PPI therapy, and an umbrella review (2025) confirmed this link across populations, finding pooled ORs ≈ 1.3–2.3 for CDI risk, although the dose–response relationship or threshold dosages remain unclear.

Long-term proton pump inhibitor use is associated with low magnesium and with vitamin B12 deficiency in observational studies. (Source 8)

• Expert review, not systematic, Low certainty.
• Size: meta-analysis of 9 studies, 109,798 patients for hypomagnesaemia; a case-control study for B12.
• Who: adults on proton pump inhibitors for two years or more.
• How long: two years or longer.
• Result: pooled risk ratio 1.43 for hypomagnesaemia (1.63 in cohort studies); significantly increased risk of vitamin B12 deficiency with long-term use, particularly at high dose.
• Funding: not stated.

A case-controlled Kaiser Permanente study found that long-term use (two years or more) of PPIs or H2RAs significantly increased the risk of vitamin B12 deficiency, particularly with high-dose PPIs. This reflects the need to consider potential B12 deficiency when prescribing acid-suppressing medications. A meta-analysis of nine studies involving 109,798 patients revealed a higher risk of hypomagnesemia with PPI use (pooled risk ratio [RR] 1.43), with an even stronger correlation in cohort studies (RR 1.63).

Proton pump inhibitor use is associated with chronic kidney disease in large cohorts, with acute interstitial nephritis as the proposed route, but the authors state this does not establish causation. (Source 18)

• Expert review, not systematic, Low certainty.
• Size: 10,482 in ARIC plus 248,751 at Geisinger; a meta-analysis of 10 observational studies with 6,829,905 people.
• Who: general-population and health-system cohorts of proton pump inhibitor users.
• How long: long-term use.
• Result: 24% and 50% increased risk of incident chronic kidney disease in the two cohorts, higher with twice-daily dosing; 72% increased risk in the pooled analysis.
• Funding: not stated.

A prospective cohort study involving 10,482 participants from Atherosclerosis Risk in Communities (ARIC) study and 248,751 patients from the Geisinger Health System showed that participants taking PPIs had a significantly higher risk of CKD incidence. PPI use was associated with a 24% and 50% increased risk of CKD in the Geisinger cohort and ARIC cohort, respectively, after adjusting for demographic, socioeconomic, and clinical factors. The risk was higher in participants on twice-daily PPI dosing. A systematic review and meta-analysis of 10 observational studies ( n = 6,829,905) revealed a 72% increased risk of developing CKD among PPI users compared to non-users. These observational findings do not infer causation, although recurrent PPI-induced interstitial nephritis is a plausible mechanism.

The introduction of a 2026 Korean nested case-control study summarises earlier meta-analyses of observational data, which put the fracture excess with proton pump inhibitors at roughly 20 to 60 percent in relative terms depending on the site while finding no significant effect on bone mineral density. (Source 19)

• Case-control study, Low certainty.
• Size: effect estimates from a pooled bone-density analysis and from a meta-analysis of 18 studies covering 244,109 fracture cases, as summarised in the introduction of a 2026 nested case-control study.
• Who: adults in national and health-system databases, in the meta-analyses the paper's introduction cites.
• How long: varies by study.
• Result: as reported by the meta-analyses summarised in that introduction: no statistically significant effect on mean annualised percent change in bone mineral density (0.06; 95% CI -0.07 to 0.18); hip fracture RR 1.26 (95% CI 1.16-1.36), spine fracture RR 1.58 (1.38-1.82) and any-site fracture RR 1.33 (1.15-1.54)
• Funding: not stated.

Limit of this finding: These pooled figures are other researchers' meta-analyses, quoted in this paper's introduction; they are not this paper's own results. The paper itself is a nested case-control analysis of a Korean national health-screening cohort, and its own primary result is not used here. Because every pooled study is observational, the figures show an association between proton pump inhibitor use and fracture, not proof that the drugs cause fractures.

A systematic review and meta-analysis of observational studies reported no statistically significant effect of PPI use on mean annualized percent change in BMD (0.06; 95% CI −0.07 to 0.18). In contrast, a meta-analysis of 18 studies involving 244,109 fracture cases found that PPI use modestly increased the risk of hip fracture (RR = 1.26, 95% CI 1.16–1.36), spine fracture (relative risk [RR] = 1.58, 95% CI 1.38–1.82), and any-site fracture (RR = 1.33, 95% CI 1.15–1.54).

Eight weeks of a proton pump inhibitor caused acid-related symptoms after withdrawal in healthy volunteers who had none before, which is direct randomised evidence for rebound acid hypersecretion. (Source 20)

• Randomized trial, Moderate certainty.
• Size: 120 healthy volunteers (59 per group analysed)
• Who: healthy adult volunteers with no reflux disease.
• How long: 8 weeks esomeprazole 40 mg/day then 4 weeks placebo, versus 12 weeks placebo.
• Result: 44% (26/59) on the drug reported at least one clinically relevant acid-related symptom in weeks 9-12 versus 15% (9/59) on placebo, P<0.001; absolute difference about 29 percentage points.
• Funding: not stated in the abstract we read.

Forty-four percent (26/59) of those randomized to PPI reported > or = 1 relevant, acid-related symptom in weeks 9-12 compared with 15% (9/59; P < .001) in the placebo group.

What the evidence supports

In a systematic review of ten randomised trials, dexlansoprazole relieved heartburn and reflux symptoms better than placebo, at moderate certainty of evidence. (Source 2)

• Systematic review, Moderate certainty.
• Size: 10 randomised controlled trials (3 pooled in the meta-analysis of heartburn-free days)
• Who: adults with erosive and non-erosive gastro-oesophageal reflux disease.
• How long: 4 weeks to 6 months across included trials.
• Result: Pooled odds ratios for 24 h heartburn-free days versus placebo were 0.04 (95% CI 0.00-0.57, I2 96.4%) for 30 mg and 0.04 (95% CI 0.01-0.30, I2 96.8%) for 60 mg; the review's own narrative reads these as more heartburn-free days on drug, so the reported direction of the odds ratio is internally inconsistent and the heterogeneity is extreme.
• Funding: independent - the review states it received no external funding.

Limit of this finding: The review's own numbers point the other way from its words: it reports odds ratios of 0.04 for 24-hour heartburn-free days "compared to the placebo medications" while concluding that the drug produced MORE heartburn-free days, and the trials it pooled disagreed with each other almost completely (I2 about 96%). Take the direction of benefit from the review's wording, not from those odds ratios, and treat the pooled size of the effect as unreliable.

Dexlansoprazole outperformed the placebo and other PPIs in the resolution of heartburn and reflux symptoms in patients with GERD, with benefits during and after treatment, especially in those with moderate and severe symptoms. The meta-analyses indicated that dexlansoprazole at doses of 30 and 60 mg had more 24 h heartburn-free days and nights compared to the placebo medications; no difference was reported between dexlansoprazole at doses of 30 and 60 mg in heartburn-free nights. A low bias risk and a moderate certainty of evidence were observed.

What the evidence does not support

One of the randomised trials inside that review found no statistically significant difference between dexlansoprazole 30 mg and placebo. (Source 21)

• Systematic review, Low certainty.
• Size: 1 trial within the 10-trial review.
• Who: patients with gastro-oesophageal reflux disease.
• How long: not stated in the passage.
• Result: absence of heartburn 86.6% on dexlansoprazole 30 mg versus 68.1% on placebo, reported as not statistically significant.
• Funding: not stated for the individual trial.

Conversely, one study found no statistical difference between the dexlansoprazole (30 mg) and the placebo groups; however, the absence of heartburn was 86.6% and 68.1% for these groups, respectively.

Against esomeprazole 40 mg in an on-demand regimen, dexlansoprazole 60 mg did not produce better sustained healing or fewer relapses over 24 weeks. (Source 22)

• Randomized trial, Low certainty.
• Size: 86 randomised, 81 analysed per protocol.
• Who: adults in Taiwan with Los Angeles grade A or B erosive esophagitis after 8 weeks of initial therapy.
• How long: 24 weeks of on-demand treatment after 8 weeks' initial therapy.
• Result: sustained healing 79.1% (34/43, 95% CI 64.0-90.0%) with dexlansoprazole versus 76.7% (33/43, 95% CI 61.3-88.2%) with esomeprazole, P=0.795 by intention to treat; secondary outcomes also not different; dexlansoprazole had fewer days with reflux symptoms (37.3+/-37.8 vs 53.9+/-54.2, P=0.008)
• Funding: independent - supported by the Research Foundation of Chang Gung Memorial Hospital; single centre, small, open comparison.

The primary outcome of SHE for the dexlansoprazole and esomeprazole groups were 79.1% (34/43, 95% CI=64.0–90.0%) vs 76.7% (33/43, 95% CI=61.3–88.2%, P =0.795) in the intention-to-treat analysis; and 85.0% (34/40, 95% CI=70.2–94.3%) vs 80.5% (33/41, 95% CI=65.2–91.2%, P =0.591) in the per-protocol analysis, which did not exhibit differences between the two groups.

That same three-year randomised trial did not confirm the pneumonia, fracture, kidney disease, dementia, cancer or mortality harms reported in observational studies. (Source 16)

• Randomized trial, High certainty.
• Size: 17,598 participants.
• Who: adults with stable cardiovascular and peripheral artery disease.
• How long: median 3.01 years.
• Result: proportions similar between groups for all other prespecified safety outcomes; C. difficile infection was about twice as common on drug but rested on only 13 events and was not statistically significant.
• Funding: not stated in the abstract we read.

For all other safety outcomes, proportions were similar between groups except for C difficile infection, which was approximately twice as common in the pantoprazole vs the placebo group, although there were only 13 events, so this difference was not statistically significant.

Where the evidence is mixed

The authors of that same systematic review warn their own result should be read cautiously because so few trials were available. (Source 2)

• Systematic review, Moderate certainty.
• Size: 10 randomised controlled trials.
• Who: adults with gastro-oesophageal reflux disease.
• How long: not applicable.
• Result: no numeric effect; a stated limitation of the review.
• Funding: independent - no external funding.

However, the interpretation of the results should be carried out cautiously due to the small number of included studies and other reported limitations.

The fracture evidence is genuinely split: pooled observational studies show more fractures, while prospective cohorts and randomised bone-density data do not. (Source 23)

• Expert review, not systematic, Low certainty.
• Size: a 32-study systematic review and meta-analysis against two prospective cohorts.
• Who: long-term proton pump inhibitor users, with emphasis on older people.
• How long: a year or longer.
• Result: increased risk of any-site, hip and spine fracture and osteoporosis in the pooled analysis; no change in bone mineral density or fracture risk in the Targownik cohorts; randomised trials show no clear effect on bone density.
• Funding: not stated.

Limit of this finding: The review's reference numbering is inconsistent between its own sections - the numbers used here for bone-density studies are used elsewhere in the same article for Clostridioides difficile claims - so its numbered pointers cannot be relied on to identify which study is which. What this finding reports is the two-sided conclusion the review itself draws: an association in the pooled observational data, no change in bone density in the prospective cohorts, and causation not established.

While several prospective observational studies indicated reduced bone mineral density with long-term PPI use, prospective cohort studies by Targownik et al. found no changes in bone mineral density or increased fracture risk. However, a systematic review and meta-analysis of 32 studies showed an increased risk of any-site fractures, hip fractures, spine fractures, and osteoporosis in PPI users. These conflicting findings suggest observational associations that may be confounded; causality is not firmly established, and randomised trials show no clear detrimental effect on bone density.

Where the research disagrees

Whether years of proton pump inhibitor use actually causes fractures, kidney disease, dementia and pneumonia, or whether the associations are confounding

• Andrawes and colleagues, reviewing the observational literature (2025), narrative review of cohort and case-control studies: A systematic review and meta-analysis of 10 observational studies ( n = 6,829,905) revealed a 72% increased risk of developing CKD among PPI users compared to non-users. These observational findings do not infer causation, although recurrent PPI-induced interstitial nephritis is a plausible mechanism. (Source 18)
• Moayyedi and colleagues, reporting the randomised COMPASS safety substudy (2019), randomised double-blind placebo-controlled trial, 17,598 participants, median 3.01 years: For all other safety outcomes, proportions were similar between groups except for C difficile infection, which was approximately twice as common in the pantoprazole vs the placebo group, although there were only 13 events, so this difference was not statistically significant. (Source 16)

Whether dexlansoprazole's dual delayed-release formulation gives a clinically better result than a conventional once-daily proton pump inhibitor

• Nascimento and colleagues, systematic review (2024), systematic review of 10 randomised trials with GRADE: This review confirms the therapeutic effect of dexlansoprazole (placebo-controlled) and its improvements in GERD symptoms compared to another PPI. (Source 2)
• The Taiwanese randomised on-demand trial (2019), single-centre randomised trial, 86 patients, 24 weeks: The primary outcome of SHE for the dexlansoprazole and esomeprazole groups were 79.1% (34/43, 95% CI=64.0–90.0%) vs 76.7% (33/43, 95% CI=61.3–88.2%, P =0.795) in the intention-to-treat analysis; and 85.0% (34/40, 95% CI=70.2–94.3%) vs 80.5% (33/41, 95% CI=65.2–91.2%, P =0.591) in the per-protocol analysis, which did not exhibit differences between the two groups. (Source 22)

How much

• Reference intake: There is no reference intake for a drug. Dosing is set by the prescriber. As a dated position, the FDA label revised 2/2025 gives 60 mg once daily for up to eight weeks to heal erosive esophagitis, and 30 mg once daily for maintenance or for symptomatic non-erosive GERD, taken without regard to food. (Source 24)
• Upper limit: No tolerable upper intake level exists for a drug. The highest dose in the FDA label revised 2/2025 is one 60 mg capsule once daily; for moderate hepatic impairment the label caps healing treatment at 30 mg once daily. (Source 24)
• Studied: Randomised trials in the 2024 systematic review used dexlansoprazole 30 mg, 60 mg and in one maintenance trial 60 to 90 mg daily. (Source 21)
• Studied: The head-to-head on-demand trial used dexlansoprazole 60 mg against esomeprazole 40 mg for 8 weeks then on demand for 24 weeks. (Source 22)
• Studied: The adolescent study used an open-label healing phase followed by 30 mg once daily or placebo for 16 weeks. (Source 3)

A common belief, and what the research shows

The belief: Heartburn that comes back as soon as you stop a proton pump inhibitor proves you still need the drug.

What the research shows: A randomised placebo-controlled trial in healthy volunteers with no reflux disease found that eight weeks of esomeprazole alone produced acid-related symptoms after withdrawal: "Forty-four percent (26/59) of those randomized to PPI reported > or = 1 relevant, acid-related symptom in weeks 9-12 compared with 15% (9/59; P < .001) in the placebo group." The authors concluded that "PPI therapy for 8 weeks induces acid-related symptoms in healthy volunteers after withdrawal." So post-stopping heartburn can be the drug's own withdrawal effect rather than the underlying condition.

Questions and answers

What is it?

Dexlansoprazole is a prescription proton pump inhibitor: the R-enantiomer of lansoprazole, packaged as a capsule with two kinds of delayed-release granules. It is one of the substituted benzimidazoles, a chemical family that blocks the stomach's acid pump. It comes in 30 mg and 60 mg capsules and is licensed in the United States from age 12. (Source 1)

What does it do in the body?

It switches off the hydrogen/potassium ATPase on the acid-secreting cells of the stomach lining, which is the final step in producing stomach acid. With less acid, reflux into the oesophagus is less corrosive, so eroded areas can heal and heartburn eases. This is the same mechanism as every other drug in the class. (Source 25)

Is it good or bad for you?

It depends almost entirely on duration and indication. For a defined course - eight weeks to heal an eroded oesophagus, four weeks for non-erosive heartburn - randomised trials support benefit and side effects are mostly mild and only a little above placebo. Used indefinitely without a reason to continue, it carries the long-term signals of the class: enteric infection, low magnesium and B12, kidney disease and fracture associations, plus rebound symptoms on stopping. The one large randomised trial over three years found only enteric infections clearly increased, so the size of the long-term risk is disputed. (Source 4)

How do you get more of it?

Dexlansoprazole is available only on prescription and there is no way to obtain more of it from food or behaviour. The only quantities with evidence behind them are the label's doses and the doses used in trials: 60 mg once daily for healing, 30 mg once daily for maintenance or non-erosive reflux. Nothing here is advice about what anyone should take. (Source 24)

If it is harmful, what reduces it?

What reduces exposure is stopping or stepping down the drug, which is the subject of a real literature. Guideline positions summarised in a 2025 review accept both a gradual taper and abrupt cessation, with on-demand or intermittent use as a middle path, and the review's own knowledge-gaps section says the best method has not been established. People who have been on it for weeks should expect rebound heartburn. (Source 5)

Why might someone be low in it or missing it?

Not having it is the normal state - it is a medicine, not something the body makes. The reasons someone would be taken off it, or would never be started, are the ones guidelines list: no continuing indication, resolved symptoms after a short course, or a preference for an H2-receptor antagonist. Conversely the review names conditions in which it should not be stopped, such as Barrett's oesophagus and severe grade C or D oesophagitis. (Source 13)

Which whole foods contain it or feed it?

No whole food contains dexlansoprazole or feeds it; it is a manufactured medicine. Food does change its absorption a little - peak levels rise by 12 to 55% and total exposure by 9 to 37% when it is taken fed rather than fasting - but the label concludes this does not matter clinically and that it can be taken with or without food. (Source 9)

What happens if you do not have it?

Nobody needs dexlansoprazole to be healthy. What matters is what happens to the condition if acid suppression is withdrawn when it is still needed: in adolescents with healed erosive esophagitis, healing was maintained in 82% on the drug versus 58% on placebo over 16 weeks, so relapse is the realistic consequence in that group. In people without a continuing indication, the evidence points the other way: stopping is what guidelines advise. (Source 3)

How can you test for it?

There is no routine blood test for dexlansoprazole itself, and none is needed. What gets tested is the condition and the consequences: upper endoscopy grades erosive esophagitis and confirms healing, which is how the trials measured their primary outcome, and magnesium, vitamin B12 and kidney function are the laboratory values the long-term harm literature concerns. The on-demand trial defined its endpoint endoscopically. (Source 26)

References

1. DailyMed / Takeda Pharmaceuticals America, Inc.. DEXILANT (dexlansoprazole) capsule, delayed release - full prescribing information (Revised: 2/2025). 2025. Read the source
2. International Journal of Molecular Sciences. The Effect of Dexlansoprazole on Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis. 2024. PMID 38279248, DOI 10.3390/ijms25021247. Read the source
3. Digestive Diseases and Sciences. Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents. 2019. PMID 30390234, DOI 10.1007/s10620-018-5325-8. Read the source
4. Medicina (Kaunas). Proton Pump Inhibitors (PPIs)—An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing. 2025. PMID 41010960, DOI 10.3390/medicina61091569. Read the source
5. Medicina (Kaunas). Proton Pump Inhibitors (PPIs)—An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing. 2025. PMID 41010960, DOI 10.3390/medicina61091569. Read the source
6. DailyMed / Takeda Pharmaceuticals America, Inc.. DEXILANT (dexlansoprazole) capsule, delayed release - full prescribing information (Revised: 2/2025). 2025. Read the source
7. DailyMed / Takeda Pharmaceuticals America, Inc.. DEXILANT (dexlansoprazole) capsule, delayed release - full prescribing information (Revised: 2/2025). 2025. Read the source
8. Medicina (Kaunas). Proton Pump Inhibitors (PPIs)—An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing. 2025. PMID 41010960, DOI 10.3390/medicina61091569. Read the source
9. DailyMed / Takeda Pharmaceuticals America, Inc.. DEXILANT (dexlansoprazole) capsule, delayed release - full prescribing information (Revised: 2/2025). 2025. Read the source
10. DailyMed / Takeda Pharmaceuticals America, Inc.. DEXILANT (dexlansoprazole) capsule, delayed release - full prescribing information (Revised: 2/2025). 2025. Read the source
11. DailyMed / Takeda Pharmaceuticals America, Inc.. DEXILANT (dexlansoprazole) capsule, delayed release - full prescribing information (Revised: 2/2025). 2025. Read the source
12. Gastroenterology. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. 2009. PMID 19362552, DOI 10.1053/j.gastro.2009.03.058. Read the source
13. Medicina (Kaunas). Proton Pump Inhibitors (PPIs)—An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing. 2025. PMID 41010960, DOI 10.3390/medicina61091569. Read the source
14. Medicina (Kaunas). Proton Pump Inhibitors (PPIs)—An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing. 2025. PMID 41010960, DOI 10.3390/medicina61091569. Read the source
15. DailyMed / Takeda Pharmaceuticals America, Inc.. DEXILANT (dexlansoprazole) capsule, delayed release - full prescribing information (Revised: 2/2025). 2025. Read the source
16. Gastroenterology. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. 2019. PMID 31152740, DOI 10.1053/j.gastro.2019.05.056. Read the source
17. Medicina (Kaunas). Proton Pump Inhibitors (PPIs)—An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing. 2025. PMID 41010960, DOI 10.3390/medicina61091569. Read the source
18. Medicina (Kaunas). Proton Pump Inhibitors (PPIs)—An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing. 2025. PMID 41010960, DOI 10.3390/medicina61091569. Read the source
19. Journal of Clinical Medicine. Association Between the Use of Proton Pump Inhibitors and Osteoporosis/Fracture: Nested Case—Control Studies Using a National Health Screening Cohort. 2026. PMID 42194677, DOI 10.3390/jcm15103716. Read the source
20. Gastroenterology. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. 2009. PMID 19362552, DOI 10.1053/j.gastro.2009.03.058. Read the source
21. International Journal of Molecular Sciences. The Effect of Dexlansoprazole on Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis. 2024. PMID 38279248, DOI 10.3390/ijms25021247. Read the source
22. Drug Design, Development and Therapy. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial. 2019. PMID 31118571, DOI 10.2147/DDDT.S193559. Read the source
23. Medicina (Kaunas). Proton Pump Inhibitors (PPIs)—An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing. 2025. PMID 41010960, DOI 10.3390/medicina61091569. Read the source
24. DailyMed / Takeda Pharmaceuticals America, Inc.. DEXILANT (dexlansoprazole) capsule, delayed release - full prescribing information (Revised: 2/2025). 2025. Read the source
25. Medicina (Kaunas). Proton Pump Inhibitors (PPIs)—An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing. 2025. PMID 41010960, DOI 10.3390/medicina61091569. Read the source
26. Drug Design, Development and Therapy. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial. 2019. PMID 31118571, DOI 10.2147/DDDT.S193559. Read the source